Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis

Overview

The purpose of this study is to evaluate patient perceptions of olopatadine 0.2% dosed once daily in patients previously treated with twice-daily, topical, ocular, anti-allergy medications.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2010

Interventions

  • Drug: Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
    • Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis

Arms, Groups and Cohorts

  • Experimental: Olopatadine 0.2%
    • 1 drop self-administered in each eye once daily in the morning for 7 days

Clinical Trial Outcome Measures

Primary Measures

  • Overall Patient Satisfaction
    • Time Frame: Day 0
    • Overall satisfaction was assessed by the patient on a questionnaire. The patient was instructed to select a single response to the statement, “Overall, how satisfied are you with your current eye allergy medication?” A 5-point scale was used: very satisfied, satisfied, undecided, dissatisfied, very dissatisfied. Results are reported as the percentage of patients who responded, “very satisfied” or “satisfied.”
  • Overall Patient Satisfaction
    • Time Frame: Day 7
    • Overall satisfaction was assessed by the patient on a questionnaire. The patient was instructed to select a single response to the statement, “Overall, how satisfied were you with olopatadine 0.2%?” A 5-point scale was used: very satisfied, satisfied, undecided, dissatisfied, very dissatisfied. Results are reported as the percentage of patients who responded, “very satisfied” or “satisfied.”

Participating in This Clinical Trial

Inclusion Criteria

  • 12 years of age or older. – History (within the past 24 months) of allergic conjunctivitis. – Active signs and symptoms of ocular allergies. – Ocular health within normal limits, as determined by the investigator or subinvestigator. – Willing to avoid contact lens wear each study visit immediately prior to study medication instillation and for 10 minutes after instillation of study drug. – Other protocol-defined inclusion criteria may apply. Exclusion Criteria:

  • Contraindications or hypersensitivity to study medication or its components. – One sighted eye or not correctable to 0.6 logMAR or better in both eyes at the screening visit. – Known history of recurrent corneal erosion syndrome. – Ocular trauma or surgical intervention within 6 months prior to Visit 1. – Participation in any other investigational study within 30 days before Visit 1. – Pregnant or nursing. – Other protocol-defined exclusion criteria may apply.

Gender Eligibility: All

Minimum Age: 12 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Alcon Research
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.